Pharmacoeconomics of elderly vaccination against invasive pneumococcal infections:Cost-effectiveness analyses and implications for the Netherlands
We performed a review of cost-effectiveness of elderly pneumococcal vaccination to prevent invasive disease. It concerns studies in the USA, Canada, Netherlands and Spain and a multinational study of five European countries. Cost-effecfiveness of elderly vaccination against invasive pneumococcal infections varies from cost-saving to €33,000 per life-year gained. The Dutch study estimates cost-effecfiveness at €10,100 per life-year gained (price level: 1995). This is below the level that has recently been defined for treatment of high cholesterol (€20,000 per life-year gained) and may therefore... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2003 |
Reihe/Periodikum: | Postma , M J , Beutels , P & Jager , J C 2003 , ' Pharmacoeconomics of elderly vaccination against invasive pneumococcal infections : Cost-effectiveness analyses and implications for the Netherlands ' , Expert review of vaccines , vol. 2 , no. 4 , pp. 477-482 . https://doi.org/10.1586/14760584.2.4.477 |
Schlagwörter: | 23-valent pneumococeal vaccine / Netherlands / Pharmacoeconomics / Review |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-27599984 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://hdl.handle.net/11370/1ac9450b-c991-4819-9f96-545db3d146ba |